Sep 3, 2026LATEST SOURCED
other
Superluminal takes its first drug clinical
Investors undisclosed
Amount$60MValuationUndisclosed
← Company explorer
Captables
SU
COMPANY PROFILE
Superluminal
Tracked in the Captables newsroom
Historical ranking valuationUndisclosedNo reviewed valuation record
Disclosed primary funding in this record
Not establishedSum of non-overlapping disclosed USD amounts in confirmed primary financing entries in this record, including separately labeled equity components; not verified lifetime funding. Excludes amounts already included in a later round, announced, reported, database-only, debt, secondary and unclassified events.
0 confirmed primary rounds with disclosed USD amounts · Record through 2026-11-01THE BUSINESS
Get to know Superluminal.
Its platform builds detailed pictures of how GPCR proteins move and how molecules can bind to different three-dimensional forms of those proteins. Superluminal then uses computational chemistry and predictive models to design and screen potential drugs. The company develops its own pipeline and also works with pharmaceutical partners, including Eli Lilly, giving it both an asset-development path and a partnership-based commercial route.
Business context from our coverage From coverage published Sep 4, 2026Valuation history
Valuations reported at the time of each round.
No dated financing valuation has passed into this record.
Funding history
Funding rounds, debt and other financing events.
1sourced event · record as of 2026-11-01
Headline association; not a reviewed issuer link. Unlinked article observations are not independently reconciled financing events. This is covered public-source history, not an exhaustive issuer ledger.
Financing participants
Investors, lenders and other parties named in funding announcements.
No named participant has been added to this company’s public financing record.
Ownership evidence
Opening ownership research…
Captables coverage
Deals / Captables
Superluminal raises $60M to move its rare-obesity drug into human trials
Superluminal uses structural biology and machine learning to design drugs for difficult cell receptors; its Series B funds a first human trial in rare genetic obesity.
Captables Newsroom · 58d ago